Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptor

Class

Small molecule MABA (muscarinic antagonist / beta-2 agonist, single-molecule dual pharmacology)

Pathway

Combined anticholinergic bronchodilation (M3 antagonism) and adrenergic bronchodilation (beta-2 agonism) in one inhaled molecule; developed for COPD

Notes

original target text: Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptor (dual)

This mechanism targets airway smooth muscle tone through two complementary receptor systems: the M3 muscarinic acetylcholine receptor and the beta-2 adrenergic receptor. Acetylcholine acting on M3 receptors promotes bronchoconstriction, so blocking this receptor (antagonism) relaxes airway smooth muscle. Beta-2 adrenergic receptors, when activated by an agonist, independently signal to relax the same muscle through a different intracellular pathway. Combining both actions in a single inhaled molecule, rather than administering separate antagonist and agonist drugs, ensures that both pharmacologies reach the airway simultaneously and in matched proportion, since a single molecule cannot deposit unevenly the way two co-administered inhalers might. This approach, known as dual pharmacology or single-molecule combination bronchodilation, is used in chronic obstructive pulmonary disease (COPD), where persistent airflow limitation results from chronic bronchoconstriction, mucus hypersecretion, and structural airway changes. Because the two receptor pathways act through distinct signaling mechanisms, their bronchodilating effects are considered complementary rather than redundant, potentially producing greater or more consistent airway opening than either mechanism alone. This class of therapy addresses the practical and mechanistic rationale for maximizing bronchodilation while simplifying inhaled treatment regimens for a disease requiring long-term, repeated dosing.